WeightWatchers has completed its financial reorganization and announced plans to launch a new program supporting women through perimenopause, menopause, and postmenopause later this year. The company has appointed Dr. Kim Boyd as Chief Medical Officer to lead clinical strategy and program innovation as it expands beyond traditional weight management.
The menopause program will integrate tailored nutritional and behavioral strategies with specialized clinical care, coaching, and community support to address the distinct metabolic health needs of women during this life stage. WeightWatchers positions the expansion as addressing a gap in healthcare where menopause has been underserved by scientific and medical communities.
“This is a pivotal moment for WeightWatchers,” said Tara Comonte, CEO of WeightWatchers. “With renewed financial strength, an expanded leadership team, and the addition of Dr. Kim Boyd to lead clinical strategy and program innovation, we’re accelerating our transformation.”
Dr. Boyd brings extensive experience in metabolic health, women’s health, and obesity care from leadership roles at One Medical, Calibrate, Caire, Galileo, and Nurx. She has co-founded or scaled multiple consumer health companies and worked with leading researchers in translating science into clinical care.
“WeightWatchers’ mission has never been more important, with nearly three-quarters of Americans and more than two billion people around the world affected by obesity or excess weight,” said Dr. Boyd. “We’re expanding that legacy by combining the best tools of modern medicine, like GLP-1s, with science-backed lifestyle change and the power of community.”
The company reports that its existing program has demonstrated strong results among women in the menopause life stage, delivering sustained weight loss that significantly outperforms self-directed approaches. The new program builds on this foundation by creating a more comprehensive experience integrating clinical care with lifestyle interventions.
WeightWatchers has also expanded its leadership team with appointments including Uta Knablein as Chief Product Officer, bringing over 20 years of digital transformation experience from companies including iHeartMedia and JPMorgan Chase. Additional executive appointments span marketing, content strategy, operations, and consumer research.
The company’s board transition includes Mike Mason, former President of Eli Lilly’s Diabetes and Obesity business, where he oversaw GLP-1 medication development and launches. His appointment signals WeightWatchers’ focus on integrating medical treatments with lifestyle interventions.
“As medical treatments like GLP-1s become more widely used, the need for trusted, comprehensive care models that combine medication with lasting lifestyle change has never been greater,” said Mason.
WeightWatchers successfully relisted as a public company on Nasdaq under ticker WW following its financial reorganization. The menopause program represents the company’s first integrated women’s health initiative, building on more than 60 years of weight management experience and its position as the most studied commercial weight management program globally.
